Doxorubicin Action on Mitochondria: Relevance to Osteosarcoma Therapy?

Author(s): Jo Armstrong, Crispin R. Dass*

Journal Name: Current Drug Targets

Volume 19 , Issue 5 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: The mitochondria may very well determine the final commitment of the cell to death, particularly in times of energy stress. Cancer chemotherapeutics such as the anthracycline doxorubicin perturb mitochondrial structure and function in tumour cells, as evidenced in osteosarcoma, for which doxorubicin is used clinically as frontline therapy. This same mechanism of cell inhibition is also pertinent to doxorubicin’s primary cause of side-effects, that to the cardiac tissue, culminating in such dire events as congestive heart failure. Reactive oxygen species are partly to blame for this effect on the mitochondria, which impact the electron transport chain.

Objective: As this review highlights that, there is much more to be learnt about the mitochondria and how it is affected by such effective but toxic drugs as doxorubicin.

Conclusion: Such information will aid researchers who search for cancer treatment able to preserve mitochondrial number and function in normal cells.

Keywords: Doxorubicin, mitochondria, cancer, osteosarcoma, apoptosis, bone.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 19 March, 2018
Page: [432 - 438]
Pages: 7
DOI: 10.2174/1389450116666150416115852
Price: $65

Article Metrics

PDF: 25
HTML: 14
PRC: 1